The board of directors of Sino Biopharmaceutical Limited announced that the phase III clinical trial results of "Anlotinib Hydrochloride Capsules" ("Anlotinib") (product name: FOCUS V), an antitumor drug self-developed by the Group, for the treatment of patients with solid tumors have been verbally reported at the 2021 American Society of Clinical Oncology ("ASCO") Annual Meeting, thus becoming the first innovative drug in the PRC that has obtained positive results from overseas registered phase III clinical studies in the field of solid tumors. Anlotinib made its debut disclosure of APROMISS Phase III clinical trials results for various advanced soft tissue sarcomas at the 2021 ASCO Annual Meeting. According to the relevant data, Anlotinib has better control over the disease and longer progression-free survival period in the treatment of patients with advanced synovial sarcoma as compared with the control group of Dacarbazine (a drug currently used in the United States for the treatment of soft tissue sarcoma). Anlotinib has been approved in the PRC for the treatment of four major indications, namely advanced non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, and medullary thyroid carcinoma. Furthermore, the use of Anlotinib in combination with chemotherapy, PD-1, and PD-L1 is under wide- scope deployment. At present, more than 20 clinical trials have entered phase II or phase III. Clinical studies of Anlotinib as a single agent have also entered Phase II or Phase III for more than 10 cancer types. Looking forward to benefiting more patients in the PRC and even the world, the Group will further expedite clinical development of innovative drugs at global level.